Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 11/20 | 1.00 |
| ▸ | HTR2A | P28223 | 4/20 | 1.00 |
| ▸ | HTR2C | P28335 | 4/20 | 1.00 |
| ▸ | HTR2B | P41595 | 4/20 | 1.00 |
| ▸ | HTR6 | P50406 | 4/20 | 1.00 |
| ▸ | HTR1D | P28221 | 3/20 | 1.00 |
| ▸ | HTR1E | P28566 | 3/20 | 1.00 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.80 |
| ▸ | HTR1A | P08908 | 1/20 | 0.72 |
| ▸ | HTR3A | P46098 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12340041 | 0.89 | SOS1 (1.00) | HTR7HTR2AHTR2CHTR2BHTR6 | |
| Hydrochloric Acid SCHEMBL3441395 | 0.88 | SOS1 (0.97) | HTR7HTR2AHTR2CHTR2BHTR6 | |
| SCHEMBL20546707 | 0.84 | HTR7 (1.00) | HTR7HTR2AHTR2CHTR2BHTR6 | |
| SCHEMBL20546703 | 0.83 | HTR7 (1.00) | HTR7HTR2AHTR2CHTR2BHTR6 | |
| SCHEMBL20547146 | 0.82 | HTR7 (1.00) | HTR7HTR2AHTR2CHTR2BHTR6 | |
| SCHEMBL7023485 | 0.76 | HTR7 (0.61) | HTR7HTR2AHTR2CHTR2BHTR6 | |
| SCHEMBL20547332 | 0.75 | HTR7 (1.00) | HTR7HTR2AHTR2CHTR2BHTR6 | |
| SCHEMBL18934294 | 0.73 | HTR7 (0.80) | HTR7HTR2AHTR2CHTR2BHTR6 | |
| SCHEMBL5644368 | 0.73 | HTR7 (0.80) | HTR7HTR2AHTR2CHTR2BHTR6 | |
| SCHEMBL20547290 | 0.73 | HTR7 (1.00) | HTR7HTR2AHTR2CHTR2BHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3560927-A1 | AZEPINE DERIVATIVE ACTING AS 5-HT7 RECEPTOR MODULATOR | Korea Institute of Science and Technology (KR) | 2019-10-30 | — | — | EP | claimed |
| US-10435408-B2 | Azepine derivatives as 5-HT7 receptor modulators | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2019-10-08 | — | — | US | claimed |
| US-20180312509-A1 | AZEPINE DERIVATIVES AS 5-HT7 RECEPTOR MODULATORS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2018-11-01 | — | — | US | claimed |
| EP-3560927-B1 | AZEPINE DERIVATIVES ACTING AS 5-HT7 RECEPTOR MODULATORS | KOREA INST SCI & TECH (KR) | 2023-04-19 | — | — | EP | disclosed |
| EP-3560927-A1 | AZEPINE DERIVATIVE ACTING AS 5-HT7 RECEPTOR MODULATOR | Korea Institute of Science and Technology (KR) | 2019-10-30 | — | — | EP | disclosed |
| US-10435408-B2 | Azepine derivatives as 5-HT7 receptor modulators | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2019-10-08 | — | — | US | disclosed |
| US-20180312509-A1 | AZEPINE DERIVATIVES AS 5-HT7 RECEPTOR MODULATORS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2018-11-01 | — | — | US | disclosed |
| US-7897771-B2 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-01 | — | — | US | disclosed |
| US-20110040088-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-17 | — | — | US | disclosed |
| US-20090270370-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-29 | — | — | US | disclosed |
| US-7579470-B2 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA NV (BE) | 2009-08-25 | — | — | US | disclosed |
| EP-1668014-B1 | FUSED HETEROCYCLIC COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-01-14 | — | — | EP | disclosed |
| US-7402680-B2 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-07-22 | — | — | US | disclosed |
| EP-1944306-A1 | Fused heterocyclic compounds as serotonin receptor modulators | Janssen Pharmaceutica, N.V. (BE) | 2008-07-16 | — | — | EP | disclosed |
| US-20080103132-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2008-05-01 | — | — | US | disclosed |
| EP-1905774-A1 | Fused heterocyclic compounds as serotonin receptor modulators | Janssen Pharmaceutica, N.V. (BE) | 2008-04-02 | — | — | EP | disclosed |
| US-20050119295-A1 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119295-A1 | Fused heterocyclic compounds | TPH1, HTR3A, HTR3B | HTR7 17/4885HTR2A 9/4885HTR2C 5/4885 |
| US-20110040088-A1 | FUSED HETEROCYCLIC COMPOUNDS | TPH1, HTR3A, HTR3B | HTR7 17/4885HTR2A 9/4885HTR2C 5/4885 |
| US-20180312509-A1 | AZEPINE DERIVATIVES AS 5-HT7 RECEPTOR MODULATORS | HTR7, HTR5A, HTR3A | HTR7 1/4885HTR2A 7/4885HTR2C 10/4885 |
| US-20090270370-A1 | FUSED HETEROCYCLIC COMPOUNDS | TPH1, HTR3A, HTR3B | HTR7 17/4885HTR2A 9/4885HTR2C 5/4885 |
| US-20080103132-A1 | FUSED HETEROCYCLIC COMPOUNDS | TPH1, HTR3A, HTR3B | HTR7 17/4885HTR2A 9/4885HTR2C 5/4885 |
| US-10435408-B2 | Azepine derivatives as 5-HT7 receptor modulators | HTR7, HTR5A, HTR3A | HTR7 1/4885HTR2A 7/4885HTR2C 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.